65,437 trials
Head Lice
Primary: Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 76…
Morbid Obesity
Primary: Percent Excess Weight Change at Day 180 — -13.2; -24.2 percentage of excess weight at screening — p=0.0520
Pain · Surgery
Primary: The Quality of Recovery Questionnaire (QoR40) on the Day (24 Hours) After Surgery — 172; 157; 173 units on a scale — p=0.006
Essential Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -18.80; -20.78 mmHg
Esophageal Cancer
Primary: Pathological Complete Response — 26 participants
Gingivitis
Primary: Gingival Index (GI) — 1.04; 1.01 units on a scale — p=<0.05
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Tremor
Primary: Tremor Amplitude — 127; 104; 150; 100 cm/s^2
Acne Vulgaris
Primary: Skin Erythema (Redness) — 1.06; 1.18; 1.26; 1.34 Units on a scale — p=> 0.05
Allergic Conjunctivitis
Primary: Overall Patient Satisfaction — 70.1 Percentage of Participants
Hepatitis C · Vasculitis
Primary: Percent of Patients in Remission — 83; 8 percent of participants
Typhoid Fever
Primary: Number of Subjects Reporting Any Post Immunization Reactions — 18; 19; 22; 16 participants
Opiate Dependence · Depression
Primary: Percentage of Participants Who Dropped Out of Buprenorphine Treatment — 33.3; 44.0 percentage of participants — p=.19
Contraception · Libido
Primary: Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS) — 6.45; 5.98 scores on a scale
Kidney Neoplasms · Carcinoma, Renal Cell
Primary: Percentage of Participants With Objective Response (OR) — 22.6 Percentage of Participants